Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Business Wire•08/10/2026•16:12 ET
4
Key Highlights
- ➤Guardant360 CDx receives European CE-marking for AstraZeneca’s ETCAMAH in advanced ER-positive breast cancer
- ➤Approval covers ESR1 mutation identification in ER-positive, HER2-negative locally advanced or metastatic breast cancer
- ➤European authorization follows Guardant360 CDx approvals for ETCAMAH in the United States and Japan
- ➤31st CDx approval marks Guardant Health’s latest regulatory milestone
- ➤ETCAMAH receives its third companion diagnostic approval for Guardant360 CDx
Expert Statements
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“Guardant360 CDx offers molecular insights that can support informed treatment decisions for patients with advanced breast cancer, addressing the disease before it gets out of control.”
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“What is even more exciting is that we see tremendous potential for this type of testing protocol to transform the treatment of other cancer types to change the future of oncology.”
Guardant Health Announces Approval in Europe of Guardant360(®) CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH(™) (camizestrant) in Advanced ER-positive Breast Cancer
* Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies
Get started
Create a free account to read the full story.